Lilly Has Earned Its Last Jardiance Sales Milestone. What Growth Remains?
A $410 million milestone boosted Lilly’s third-quarter Jardiance revenue. Removing milestones from both comparison periods reveals growth that remains strong, but a lower starting point for forecasts.
Wealth / The Compound journalPhoto: Grendelkhan / Wikimedia Commons / CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/). Archival: 10 January 2024. Resized and cropped. · Illustrative image.
Eli Lilly’s Jardiance revenue rose about 65% in the September quarter, but part of that increase cannot repeat under the existing collaboration. Lilly has now earned every available sales-based milestone. For investors building a revenue forecast, the useful question is how much growth remains after removing those payments from both years.
This is an analysis of the quarter ended 30 September 2026, disclosed on 29 October, rather than a new announcement today. The distinction matters: the milestone exhaustion is already public information, not a surprise discovered after the results.
Separate the revenue share from the milestone
Under its agreement with Boehringer Ingelheim, Lilly receives a performance-dependent share of Jardiance net sales in the most significant markets. The filing says that collaboration continues through 31 December 2028. Milestone exhaustion does not mean the ongoing revenue share has ended. The product-family figures also include Glyxambi, Synjardy and Trijardy XR. Source: Form 10-Q, Note 3.
A milestone recognises a contractual achievement. A continuing share of sales depends on subsequent commercial activity. Both legitimately enter reported revenue, but treating them as equally repeatable would overstate the starting point for a forward model.
The comparison after removing milestones
All amounts below are Lilly revenue in US dollars, not worldwide sales of the medicines by every partner. Both columns cover three months ended 30 September.
| Revenue bridge, $ million | 2026 | 2025 |
|---|---|---|
| Reported Jardiance family revenue | 1,578 | 959 |
| Disclosed sales-based milestones | 410 | 200 |
| Revenue less those milestones, calculated | 1,168 | 759 |
The reported increase is $619 million, or 64.5%. Excluding the disclosed milestones from each period leaves an increase of $409 million, or 53.9%: (1,168 / 759 − 1) × 100. The additional milestone contribution is $210 million, approximately 34% of the reported dollar increase.
These are Compound calculations from Note 3, not a company-defined adjusted measure. They strip out only the identified sales milestones; they do not remove every possible pricing, currency or accounting effect. Calling the result prescription growth, volume growth or a fully normalised growth rate would go beyond the evidence.
The balance of the result is encouraging: the disclosed milestone increase does not explain most of the revenue gain. But investors should not carry the entire reported quarterly total into a recurring-revenue forecast.
A forecast needs a lower starting point
Consider a deliberately simple sensitivity. If the calculated $1,168 million base grew by an illustrative 10% in a future comparable quarter, with no new milestone, it would produce approximately $1,285 million. That would still be about 19% below this quarter’s reported $1,578 million.
This is arithmetic, not Lilly guidance or a prediction. It shows how a business can keep growing on a comparable basis while its headline revenue falls against a milestone-heavy period. Investors should diagnose the comparison before interpreting such a decline as deteriorating demand.
Nor should the $410 million be multiplied by four and labelled an annual loss. It was a particular quarter’s milestone payment, not a recurring quarterly entitlement. A proper annual model needs the full annual comparison and the timing of each adjustment.
Keep the group-level conclusion proportionate
Lilly’s earnings release separately identifies approximately $900 million of Q3 revenue benefits, primarily Jardiance milestones and favourable rebate and discount estimate adjustments. The $410 million is already within that broader description: subtracting both amounts from group revenue would double-count it.
There is also no basis here for converting every dollar of revenue into a dollar of net profit. Taxes, expenses and the economics of the collaboration matter. This analysis does not estimate an EPS reduction or a fair share price.
For the next results, the useful checks are the disclosed Jardiance revenue share, the absence of further sales milestones under the agreement, and any changes to the collaboration terms. Those observations would tell investors more about repeatability than the headline growth rate alone.
The Lilly stock profile contains the continuing financial report. Our Mounjaro China analysis examines the separate price-versus-volume question, while the METiS deal analysis explains contingent payments Lilly may make to a research partner.
Investment analysis for information, not a personal recommendation. Archival photograph by Grendelkhan, via Wikimedia Commons, CC BY-SA 4.0. Resized versions and crops retain that licence.


